Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : AcelRx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The agreement to acquire Lowell will also include LTX-608, Lowell's proprietary nafamostat formulation for direct IV infusion being developed for the treatment of acute respiratory distress syndrome (ARDS) and disseminated intravascular coagulation (DIC)...
Product Name : LTX-608
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 15, 2021
Lead Product(s) : Nafamostat
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : AcelRx Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Premier
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Researchers found that patients on a prophylactic dose of the anticoagulants enoxaparin or heparin have shorter hospital stays, lower cost, and better clinical outcomes in Covid-19 patient.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2021
Lead Product(s) : Enoxaparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Premier
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abelacimab
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Anthos Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lonza Partners with Anthos Therapeutics for Thrombosis Treatment
Details : The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
November 06, 2020
Lead Product(s) : Abelacimab
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Anthos Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : FTH1
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : SRS Life Sciences Pte ltd
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement provides SRS exclusive rights for sales, marketing, and distribution of Sidero’s patented biologic iron, BioFeTM, for the management of iron deficiency and related disorders in India and Southeast Asia.
Product Name : BioFe
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 13, 2020
Lead Product(s) : FTH1
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : SRS Life Sciences Pte ltd
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : VMX-C001
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Ysios Capital
Deal Size : $36.6 million
Deal Type : Series B Financing
Details : Proceeds to be used to achieve clinical proof of concept for lead compound, VMX-COO1, advance program to registrational studies, accelerate manufacturing trajectory towards commercial scale, and advance the discovery platform program.
Product Name : VMX-C001
Product Type : Enzyme
Upfront Cash : Undisclosed
August 07, 2020
Lead Product(s) : VMX-C001
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Ysios Capital
Deal Size : $36.6 million
Deal Type : Series B Financing
Lead Product(s) : Hematopoietic Stem Cell
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Baize Plan Fund
Deal Size : $3.6 million
Deal Type : Collaboration
Details :
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 28, 2020
Lead Product(s) : Hematopoietic Stem Cell
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Baize Plan Fund
Deal Size : $3.6 million
Deal Type : Collaboration
Lead Product(s) : Heparin Sodium
Therapeutic Area : Hematology
Study Phase : Undisclosed
Sponsor : Cerus DMCC
Deal Size : Undisclosed
Deal Type : Acquisition
CERUS Announces the Acquisition of Laboratori Derivati Organici SpA (LDO) by Opocrin SpA
Details : Transaction enables Opocrin to become a leading global producer of active biologics including heparin and heparinoids.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
April 29, 2020
Lead Product(s) : Heparin Sodium
Therapeutic Area : Hematology
Highest Development Status : Undisclosed
Sponsor : Cerus DMCC
Deal Size : Undisclosed
Deal Type : Acquisition